Skip to main content

Table 1 Clinical heterogeneity: PROWESS versus PROWESS-SHOCK - trial characteristics

From: Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis

Trial characteristic Trial Proportion with characteristic Comparison P-value
Enrolled in North America PROWESS 54.7% P < 0.0001
  PROWESS-SHOCK 14.1%  
Chronic obstructive pulmonary disease PROWESS 24.1% P < 0.0001
  PROWESS-SHOCK 15.5%  
Lung as site of infection PROWESS 53.6% P < 0.0001
  PROWESS-SHOCK 43.9%  
Presence of shock PROWESS 71% P < 0.0001
  PROWESS-SHOCK 100%  
S. pneumoniae infections PROWESS 11.9% P < 0.0001
  PROWESS-SHOCK 4.5%  
S. aureus infections PROWESS 14.3% P < 0.0001
  PROWESS-SHOCK 3.7%  
Escherichia coli infections PROWESS 16.5% P < 0.0001
  PROWESS-SHOCK 10.3%  
Klebsiella spp. Infections PROWESS 6.2% P < 0.0001
  PROWESS-SHOCK 2.2%  
Use of appropriate antibiotics PROWESS 91.2% P < 0.0001
  PROWESS-SHOCK 84.2%  
Use of steroids for septic shock PROWESS 13.5% P < 0.0001
  PROWESS-SHOCK 49.5%  
Use of heparin PROWESS 75.2% P < 0.0001
  PROWESS-SHOCK 44.7%  
Serious bleeding with drotrecogin PROWESS 3.5% P = 0.0017
  PROWESS-SHOCK 1.2%